- Home
- EXFY vs ITOS Comparison
EXFY vs ITOS Comparison
Compare EXFY & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- ITOS
- Stock Information
- Founded
- EXFY 2008
- ITOS 2011
- Country
- EXFY United States
- ITOS United States
- Employees
- EXFY N/A
- ITOS N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EXFY Technology
- ITOS Health Care
- Exchange
- EXFY Nasdaq
- ITOS Nasdaq
- Market Cap
- EXFY 253.2M
- ITOS 270.7M
- IPO Year
- EXFY 2021
- ITOS 2020
- Fundamental
- Price
- EXFY $2.38
- ITOS $6.67
- Analyst Decision
- EXFY Buy
- ITOS Strong Buy
- Analyst Count
- EXFY 4
- ITOS 3
- Target Price
- EXFY $4.75
- ITOS $25.67
- AVG Volume (30 Days)
- EXFY 336.9K
- ITOS 559.5K
- Earning Date
- EXFY 05-08-2025
- ITOS 04-28-2025
- Dividend Yield
- EXFY N/A
- ITOS N/A
- EPS Growth
- EXFY N/A
- ITOS N/A
- EPS
- EXFY N/A
- ITOS N/A
- Revenue
- EXFY $141,775,000.00
- ITOS $35,000,000.00
- Revenue This Year
- EXFY $9.56
- ITOS N/A
- Revenue Next Year
- EXFY $6.86
- ITOS $31.74
- P/E Ratio
- EXFY N/A
- ITOS N/A
- Revenue Growth
- EXFY N/A
- ITOS 177.89
- 52 Week Low
- EXFY $1.24
- ITOS $4.80
- 52 Week High
- EXFY $4.13
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- EXFY 33.37
- ITOS 49.00
- Support Level
- EXFY $2.78
- ITOS $6.18
- Resistance Level
- EXFY $3.06
- ITOS $7.80
- Average True Range (ATR)
- EXFY 0.16
- ITOS 0.50
- MACD
- EXFY -0.01
- ITOS -0.05
- Stochastic Oscillator
- EXFY 24.44
- ITOS 29.94
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.